ReviewComprehensive Physiology2026
Molecular Mechanisms and Therapeutic Potential of DJ-1 in Skeletal Muscle Homeostasis and Disease.
Review in Comprehensive Physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Mechanisms and Therapeutic Potential of DJ-1 in Skeletal Muscle Homeostasis and Disease.Comprehensive Physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The DJ-1 protein was initially identified as an oncogene, but subsequent studies revealed its crucial protective role in neurodegenerative diseases. Increasing evidence indicates that DJ-1 possesses critical physiological functions in skeletal muscle, but the underlying mechanisms remain to be systematically elucidated. Existing research has conclusively demonstrated that DJ-1 is widely expressed in skeletal muscle and functions as a central hub integrating multiple pathways to establish a multi-level cellular protection network: it safeguards energy metabolism by maintaining mitochondrial structure and function; enhances antioxidant capacity by directly scavenging ROS and regulating Nrf2/ARE signaling; and delays muscle aging by inhibiting protein aggregation and preserving protein homeostasis. Under pathological conditions, DJ-1 dysfunction is closely associated with muscular dystrophy, inflammatory myopathy, metabolic myopathy, and muscle atrophy. Its abnormalities lead to mitochondrial damage, exacerbated oxidative stress, and disrupted protein homeostasis, ultimately triggering muscle structural deterioration. Based on these insights, researchers have developed various DJ-1 regulatory strategies, including small-molecule activators, transcriptional modulators, and functional peptide compounds, which show promising therapeutic potential. This review represents the first systematic, cross-disease integration of DJ-1's role in aging-related sarcopenia, diabetic myopathy, inflammatory myopathies, and neuromuscular degenerative diseases. It elucidates DJ-1's core function as a central integrator coordinating antioxidant defense, mitochondrial homeostasis, metabolic regulation, and protein homeostasis. A deeper understanding of DJ-1's mechanisms will provide critical theoretical foundations for elucidating the common pathological basis of skeletal muscle diseases and developing novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.